Bayer’s Rally Faces a New Test: Antidumping Bid vs. Overbought Charts After Court Win

Just five days after a landmark Supreme Court victory, Bayer has opened a second front in its glyphosate saga — this time against Chinese imports. The stock has surged to within a whisker of its 52-week high, but traders are watching the charts with growing unease.

On 30 June 2026, Bayer’s Monsanto subsidiary and the newly created Ruveon LLC filed a petition with the US Department of Commerce and the International Trade Commission, seeking antidumping and countervailing duties on Chinese glyphosate. The move targets the price pressure from cheap Asian generic material that has eroded Bayer’s margins. The company — the last US-based manufacturer of the herbicide — had already forecast a 2% to 6% drop in glyphosate sales for 2026.

The petition landed less than a week after the US Supreme Court handed Bayer its biggest legal win in years. On 25 June, the justices ruled 7-2 in the Durnell case that the federal FIFRA statute pre-empts state-law claims over missing cancer warnings on glyphosate — provided the EPA has completed a final safety assessment. The decision overturned a $1.25 million verdict and effectively immunises Bayer from a wave of future lawsuits on that basis.

Rally Leaves the Stock Stretched

The market’s response has been electric. Bayer shares closed on Friday at €53.04, just 1.52% below the 52-week high of €53.86 set on 3 July. Over the past week, the stock has climbed 13.80%; over 30 days, it has soared 53.74%. Since the start of the year, the gain stands at 39.49%, and compared to the 52-week trough of €25.09 from August 2025, the stock has more than doubled — a 111.36% advance.

Yet the speed of the ascent has pushed technical readings into historically dangerous territory. The 14-day relative strength index stands at 85.1 — deep in overbought territory and well above the threshold where pullbacks typically occur. The stock now trades 36.50% above its 50-day moving average of €38.86 and 42.91% above the 200-day line of €37.11. The annualised 30-day volatility has spiked to 63.19%, underscoring the nervousness beneath the surface.

The Missing Piece: Settlement Approval Still Pending

For all the euphoria, the legal picture remains incomplete. The multibillion-dollar class-action settlement that would put the glyphosate litigation to rest has not yet been granted final approval. A Missouri court hearing initially set for early July has been postponed to 19 August 2026. Even after that date, appeals could drag on for years, as Bayer acknowledged in its own quarterly report.

Should investors sell immediately? Or is it worth buying Bayer?

Moreover, critics are already questioning the fairness of the deal, with some arguing that high attorneys’ fees could come at the expense of the affected plaintiffs. For the roughly 60,000 to 65,000 pending cases, the Supreme Court ruling weakens the legal foundation of future claims, but it does not extinguish current ones.

A Second Catalyst in the Pipeline

Bayer is not relying solely on litigation and trade action. On the pharmaceutical side, the US Food and Drug Administration is reviewing the stroke-prevention drug asundexian under an accelerated process. The company expects results in the second half of 2026 — a potential catalyst that could shift the narrative beyond glyphosate.

Still, the near-term outlook is dominated by the same question: Has the market already priced in the full benefit of the Supreme Court win before the settlement is even finalised? The antidumping petition adds another layer of uncertainty — it is unclear whether the US will open an investigation at all, let alone impose duties that meaningfully affect Bayer’s bottom line.

Chart Support and the August Hearing

With the RSI at such extreme levels, a consolidation phase looks likely. Short-term corrections are common after rallies of this magnitude, irrespective of the fundamental news flow. Should the stock retreat, the 50-day moving average near €39 is viewed as the first logical support zone. A hold above that level would suggest the re-rating is structurally sound.

The next concrete event remains the 19 August hearing in Missouri. Any fresh objections from plaintiffs’ lawyers or delays in the trade petition could puncture the rally. Conversely, a clean approval combined with progress on the China front could give the market reason to push the revaluation further.

For now, Bayer’s stock is caught between a historic legal victory and an overbought technical condition — with a new trade battle just getting started.